AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Clinical Outcomes After Non-curative Endoscopic Resection in Early Colorectal Cancer: A Multicenter Study

Recruitingn/aAges 18 Years - 75 YearsAllNanfang Hospital, Southern Medical University
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This multicenter study aims to evaluate clinical outcomes and optimize management strategies in patients with early colorectal cancer who undergo non-curative endoscopic resection. Patients with non-curative resection following endoscopic treatment will be enrolled across multiple centers and managed according to real-world clinical decisions, including additional surgery or surveillance. Baseline demographic, endoscopic, and pathological characteristics will be systematically collected. The primary objective is to compare recurrence and survival outcomes between different management strategies. Secondary objectives include identifying prognostic factors associated with recurrence and developing a risk stratification model to guide individualized treatment decisions. All participants will undergo standardized follow-up according to clinical guidelines. This study is expected to provid

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Age โ‰ฅ18 years; * Patients with early colorectal cancer confirmed by histopathology; * Patients who underwent endoscopic resection (including EMR, ESD, or equivalent techniques); * Pathological diagnosis indicating non-curative resection, defined by the presence of at least one of the following: positive resection margin, submucosal invasion depth \>1000 ฮผm, poor differentiation, lymphovascular invasion, perineural invasion, or high-grade tumor budding; * Availability of complete clinicopathological and follow-up data; * Patients managed with either additional surgery or surveillance after endoscopic resection. Exclusion Criteria: * Patients with synchronous advanced colorectal cancer or distant metastasis at baseline; * History of other active malignancies; * Patients with inflammatory bowel disease, familial adenomatous polyposis, or other hereditary colorectal cancer syndromes; * Patients who received neoadjuvant therapy before endoscopic resection; * Incomplete pathological data or missing key variables; * Loss to follow-up or follow-up duration less than 6 months.
๐Ÿ’Š

What it tests

  • Additional Surgery
  • Surveillance
๐Ÿ“

Where

3 sites
Nanfang Hospital, Southern Medical University
Guangzhou, China
Shenzhen Longgang District People's Hospital
Shenzhen, China
The Second Affiliated Hospital of Guangzhou Medical University
Haizhu, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy